Avacta pushes back annual results due to auditor delays.
Life sciences company Avacta Therapeutics has announced that it has had to delay the release of its annual results by a week.
Avacta Group
27 May 2025 09:19:21
Source: Sharecast
The company, which develops next generation peptide drug conjugates, was originally due to report its results for 2024 on 29 May, but said that auditors have been unable to finalise the audit work connected to this year's disposal of Launch Diagnostics to Palex Healthcare.
Avacta was only notified of this delay last week, and so results are now expected to be released on 4 June.
However, the company reassured investors by saying that the delay is not a result of any adverse financial developments.
"There is no impact to Avacta's financial position and cash runway," Avacta said on Tuesday.
Shares were up 3% at 28.33p by 0916 BST.
N/A
ISIN:
N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes
Compare our accounts
If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
